World Wires · story 28037 · unverified · 1 source(s)

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin

Open in the desk

Coverage

• vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease GlobeNewswire: public companies · tier D · clear net · 2026-10-07 20:01 UTC

What this site indexes